{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:54:01Z","timestamp":1790726041721,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T00:00:00Z","timestamp":1543276800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-5080-4","type":"journal-article","created":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T07:36:42Z","timestamp":1543304202000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":110,"title":["Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials"],"prefix":"10.1186","volume":"18","author":[{"given":"Shailesh M.","family":"Advani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragati G.","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena M.","family":"VonVille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3949-3482","authenticated-orcid":false,"given":"Syed H.","family":"Jafri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,27]]},"reference":[{"key":"5080_CR1","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/SPC.0b013e3283186be2","volume":"2","author":"NA Stephens","year":"2008","unstructured":"Stephens NA, Skipworth RJ, Fearon KC. Cachexia, survival and the acute phase response. Curr Opin Support Palliat Care. 2008;2:267\u201374.","journal-title":"Curr Opin Support Palliat Care"},{"key":"5080_CR2","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.2217\/fon.09.106","volume":"5","author":"MF Zilbermint","year":"2009","unstructured":"Zilbermint MF, Dobs AS. Nonsteroidal selective androgen receptor modulator Ostarine\u2122 in cancer cachexia. Future Oncol. 2009;5:1211\u201320.","journal-title":"Future Oncol"},{"key":"5080_CR3","first-page":"292","volume":"14","author":"G Mantovani","year":"2010","unstructured":"Mantovani G. Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia. Eur Rev Med Pharmacol Sci. 2010;14:292\u2013301.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"5080_CR4","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1097\/SPC.0000000000000301","volume":"11","author":"RF Dunne","year":"2017","unstructured":"Dunne RF, Mustian KM, Garcia JM, et al. Research priorities in cancer cachexia: the University of Rochester Cancer Center NCI Community Oncology Research Program Research Base Symposium on Cancer Cachexia and sarcopenia. Curr Opin Support Palliat Care. 2017;11:278\u201386.","journal-title":"Curr Opin Support Palliat Care"},{"key":"5080_CR5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489\u201395.","journal-title":"Lancet Oncol"},{"key":"5080_CR6","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/SPC.0b013e3283311c6f","volume":"3","author":"C Madeddu","year":"2009","unstructured":"Madeddu C, Mantovani G. An update on promising agents for the treatment of cancer cachexia. Curr Opin Support Palliat Care. 2009;3:258\u201362.","journal-title":"Curr Opin Support Palliat Care"},{"key":"5080_CR7","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1517\/14656560902960162","volume":"10","author":"C Madeddu","year":"2009","unstructured":"Madeddu C, Maccio A, Panzone F, et al. Medroxyprogesterone acetate in the management of cancer cachexia. Expert Opin Pharmacother. 2009;10:1359\u201366.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"5080_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1023\/A:1011156811739","volume":"12","author":"M. Maltoni","year":"2001","unstructured":"Maltoni M, Nanni O, Scarpi E, Rossi D, Serra P, Amadori D. High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials. Annals of Oncology. 2001;12(3):289\u2013300.","journal-title":"Annals of Oncology"},{"key":"5080_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s11912-005-0050-9","volume":"7","author":"KF Giordano","year":"2005","unstructured":"Giordano KF, Jatoi A. The cancer anorexia\/weight loss syndrome: therapeutic challenges. Curr Oncol Rep. 2005;7:271\u20136.","journal-title":"Curr Oncol Rep"},{"key":"5080_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.clnu.2006.05.009","volume":"25","author":"F Mateen","year":"2006","unstructured":"Mateen F, Jatoi A. Megestrol acetate for the palliation of anorexia in advanced, incurable cancer patients. Clin Nutr. 2006;25:711\u20135.","journal-title":"Clin Nutr"},{"key":"5080_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/ncponc0112","volume":"2","author":"A Laviano","year":"2005","unstructured":"Laviano A, Meguid MM, Inui A, et al. Therapy insight: Cancer anorexia-cachexia syndrome--when all you can eat is yourself. Nat Rev Clin Oncol. 2005;2:158.","journal-title":"Nat Rev Clin Oncol"},{"key":"5080_CR12","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0149-2918(05)80001-3","volume":"69","author":"WD Dewys","year":"1980","unstructured":"Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior tochemotherapy in cancer patients. Am J Med. 1980;69:491\u20137.","journal-title":"Am J Med"},{"key":"5080_CR13","doi-asserted-by":"publisher","first-page":"1143S","DOI":"10.3945\/ajcn.2010.28608E","volume":"91","author":"NP Gullett","year":"2010","unstructured":"Gullett NP, Hebbar G, Ziegler TR. Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting. Am J Clin Nutr. 2010;91:1143S\u20137S.","journal-title":"Am J Clin Nutr"},{"key":"5080_CR14","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1093\/ajcn\/83.4.735","volume":"83","author":"JE Morley","year":"2006","unstructured":"Morley JE, Thomas DR, Wilson M-MG. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006;83:735\u201343.","journal-title":"Am J Clin Nutr"},{"key":"5080_CR15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00520-009-0640-4","volume":"18","author":"LA Taylor","year":"2010","unstructured":"Taylor LA, Pletschen L, Arends J, et al. Marine phospholipids\u2014a promising new dietary approach to tumor-associated weight loss. Support Care Cancer. 2010;18:159.","journal-title":"Support Care Cancer"},{"key":"5080_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1096\/fj.10-164152","volume":"25","author":"A Doyle","year":"2011","unstructured":"Doyle A, Zhang G, Fattah EAA, et al. Toll-like receptor 4 mediates lipopolysaccharide-induced muscle catabolism via coordinate activation of ubiquitin-proteasome and autophagy-lysosome pathways. FASEB J. 2011;25:99\u2013110.","journal-title":"FASEB J"},{"key":"5080_CR17","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1038\/emboj.2011.292","volume":"30","author":"G Zhang","year":"2011","unstructured":"Zhang G, Jin B, Li YP. C\/EBP\u03b2 mediates tumour-induced ubiquitin ligase atrogin1\/MAFbx upregulation and muscle wasting. EMBO J. 2011;30:4323\u201335.","journal-title":"EMBO J"},{"key":"5080_CR18","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1038\/s41598-017-02347-2","volume":"7","author":"G Zhang","year":"2017","unstructured":"Zhang G, Liu Z, Ding H, et al. Toll-like receptor 4 mediates Lewis lung carcinoma-induced muscle wasting via coordinate activation of protein degradation pathways. Sci Rep. 2017;7:2273.","journal-title":"Sci Rep"},{"key":"5080_CR19","doi-asserted-by":"publisher","first-page":"8500","DOI":"10.1200\/JCO.2005.01.8010","volume":"23","author":"T Yavuzsen","year":"2005","unstructured":"Yavuzsen T, Davis MP, Walsh D, et al. Systematic review of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol. 2005;23:8500\u201311.","journal-title":"J Clin Oncol"},{"key":"5080_CR20","volume-title":"Excel workbooks for systematic reviews","author":"H VonVille","year":"2015","unstructured":"VonVille H. Excel workbooks for systematic reviews; 2015."},{"key":"5080_CR21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401\u20136.","journal-title":"J Clin Epidemiol"},{"key":"5080_CR22","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1200\/JCO.2005.05.1847","volume":"24","author":"F Strasser","year":"2006","unstructured":"Strasser F, Luftner D, Possinger K, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-in-Cachexia-study-group. J Clin Oncol. 2006;24:3394\u2013400.","journal-title":"J Clin Oncol"},{"issue":"9","key":"5080_CR23","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1007\/s00520-018-4154-9","volume":"26","author":"Jenny G. Turcott","year":"2018","unstructured":"Turcott JG, N\u00fa\u00f1ez MRG, Flores-Estrada D, et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer. 2018;26:3029. \n                    https:\/\/doi.org\/10.1007\/s00520-018-4154-9\n                    \n                  .","journal-title":"Supportive Care in Cancer"},{"key":"5080_CR24","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1200\/JCO.2012.43.6766","volume":"31","author":"E Del Fabbro","year":"2013","unstructured":"Del Fabbro E, Dev R, Hui D, et al. Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. J Clin Oncol. 2013;31:1271\u20136.","journal-title":"J Clin Oncol"},{"key":"5080_CR25","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S1470-2045(14)71154-4","volume":"16","author":"JM Garcia","year":"2015","unstructured":"Garcia JM, Boccia RV, Graham CD, et al. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol. 2015;16:108\u201316.","journal-title":"Lancet Oncol"},{"key":"5080_CR26","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1007\/s00520-016-3144-z","volume":"24","author":"K Takayama","year":"2016","unstructured":"Takayama K, Katakami N, Yokoyama T, et al. Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial. Support Care Cancer. 2016;24:3495\u2013505.","journal-title":"Support Care Cancer"},{"key":"5080_CR27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","volume":"17","author":"JS Temel","year":"2016","unstructured":"Temel JS, Abernethy AP, Currow DC, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016;17:519\u201331.","journal-title":"Lancet Oncol"},{"key":"5080_CR28","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1093\/annonc\/mdx192","volume":"28","author":"D Currow","year":"2017","unstructured":"Currow D, Temel J, Abernethy A, et al. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Ann Oncol. 2017;28:1949\u201356.","journal-title":"Ann Oncol"},{"key":"5080_CR29","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/cncr.31128","volume":"124","author":"N Katakami","year":"2018","unstructured":"Katakami N, Uchino J, Yokoyama T, et al. Anamorelin (ONO-7643) for the treatment of patients with non\u2013small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer. 2018;124:606\u201316.","journal-title":"Cancer"},{"key":"5080_CR30","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1007\/s00520-016-3560-0","volume":"25","author":"Y Bai","year":"2017","unstructured":"Bai Y, Hu Y, Zhao Y, et al. Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis. Support Care Cancer. 2017;25:1651\u20139.","journal-title":"Support Care Cancer"},{"key":"5080_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.lungcan.2017.07.023","volume":"112","author":"K Nishie","year":"2017","unstructured":"Nishie K, Yamamoto S, Nagata C, et al. Anamorelin for advanced non-small-cell lung cancer with cachexia: systematic review and meta-analysis. Lung Cancer. 2017;112:25\u201334.","journal-title":"Lung Cancer"},{"key":"5080_CR32","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1002\/cncr.22944","volume":"110","author":"A Jatoi","year":"2007","unstructured":"Jatoi A, Dakhil SR, Nguyen PL, et al. A placebo-controlled double blind trial of etanercept for the cancer anorexia\/weight loss syndrome. Cancer. 2007;110:1396\u2013403.","journal-title":"Cancer"},{"key":"5080_CR33","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.lungcan.2009.06.020","volume":"68","author":"A Jatoi","year":"2010","unstructured":"Jatoi A, Ritter HL, Dueck A, et al. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and\/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer. 2010;68:234\u20139.","journal-title":"Lung Cancer"},{"key":"5080_CR34","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1136\/gut.2004.047563","volume":"54","author":"J Gordon","year":"2005","unstructured":"Gordon J, Trebble T, Ellis R, et al. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut. 2005;54:540\u20135.","journal-title":"Gut"},{"key":"5080_CR35","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1089\/jpm.2012.0146","volume":"15","author":"S Yennurajalingam","year":"2012","unstructured":"Yennurajalingam S, Willey JS, Palmer JL, et al. The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study. J Palliat Med. 2012;15:1059\u201364.","journal-title":"J Palliat Med"},{"key":"5080_CR36","doi-asserted-by":"publisher","first-page":"60","DOI":"10.4103\/2277-9175.179182","volume":"5","author":"V Mehrzad","year":"2016","unstructured":"Mehrzad V, Afshar R, Akbari M. Pentoxifylline treatment in patients with cancer cachexia: a double-blind, randomized, placebo-controlled clinical trial. Adv Biomed Res. 2016;5:60.","journal-title":"Adv Biomed Res"},{"key":"5080_CR37","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1158\/1078-0432.CCR-06-2720","volume":"13","author":"K Lundholm","year":"2007","unstructured":"Lundholm K, K\u00f6rner U, Gunnebo L, et al. Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning. Clin Cancer Res. 2007;13:2699\u2013706.","journal-title":"Clin Cancer Res"},{"key":"5080_CR38","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1470-2045(13)70055-X","volume":"14","author":"AS Dobs","year":"2013","unstructured":"Dobs AS, Boccia RV, Croot CC, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013;14:335\u201345.","journal-title":"Lancet Oncol"},{"key":"5080_CR39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s13539-011-0034-6","volume":"2","author":"JT Dalton","year":"2011","unstructured":"Dalton JT, Barnette KG, Bohl CE, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle. 2011;2:153\u201361.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"5080_CR40","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1021\/jm0499007","volume":"47","author":"CE Bohl","year":"2004","unstructured":"Bohl CE, Chang C, Mohler ML, et al. A ligand-based approach to identify quantitative structure\u2212 activity relationships for the androgen receptor. J Med Chem. 2004;47:3765\u201376.","journal-title":"J Med Chem"},{"issue":"6","key":"5080_CR41","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1159\/000346446","volume":"58","author":"Hong-Sheng Wen","year":"2012","unstructured":"Wen H-S, Li X, Cao Y-Z, et al. Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide. Chemotherapy. 2012;58:461\u20137.","journal-title":"Chemotherapy"},{"key":"5080_CR42","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/030089161309900218","volume":"99","author":"O Kanat","year":"2013","unstructured":"Kanat O, Cubukcu E, Avci N, et al. Comparison of three different treatment modalities in the management of cancer cachexia. Tumori. 2013;99:229\u201333.","journal-title":"Tumori"},{"key":"5080_CR43","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1634\/theoncologist.2009-0153","volume":"15","author":"G Mantovani","year":"2010","unstructured":"Mantovani G, Macci\u00f2 A, Madeddu C, et al. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist. 2010;15:200\u201311.","journal-title":"Oncologist"},{"key":"5080_CR44","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.clnu.2011.10.005","volume":"31","author":"C Madeddu","year":"2012","unstructured":"Madeddu C, Dess\u00ec M, Panzone F, et al. Randomized phase III clinical trial of a combined treatment with carnitine+ celecoxib\u00b1megestrol acetate for patients with cancer-related anorexia\/cachexia syndrome. Clin Nutr. 2012;31:176\u201382.","journal-title":"Clin Nutr"},{"key":"5080_CR45","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1007\/s00520-018-4047-y","volume":"26","author":"B Kouchaki","year":"2018","unstructured":"Kouchaki B, Janbabai G, Alipour A, et al. Randomized double-blind clinical trial of combined treatment with megestrol acetate plus celecoxib versus megestrol acetate alone in cachexia-anorexia syndrome induced by GI cancers. Support Care Cancer. 2018;26:2479\u201389.","journal-title":"Support Care Cancer"},{"key":"5080_CR46","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00520-016-3402-0","volume":"25","author":"EJ Roeland","year":"2017","unstructured":"Roeland EJ, Ma JD, Nelson SH, et al. Weight loss versus muscle loss: re-evaluating inclusion criteria for future cancer cachexia interventional trials. Support Care Cancer. 2017;25:365\u20139.","journal-title":"Support Care Cancer"},{"key":"5080_CR47","doi-asserted-by":"crossref","unstructured":"Guillory B, Splenser A, Garcia J. The role of ghrelin in anorexia\u2013cachexia syndromes. In: Vitamins & Hormones: Elsevier; 2013;92:61\u2013106. Academic Press.","DOI":"10.1016\/B978-0-12-410473-0.00003-9"},{"key":"5080_CR48","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.2147\/DDDT.S110131","volume":"11","author":"SA Graf","year":"2017","unstructured":"Graf SA, Garcia JM. Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome: design, development, and potential place in therapy. Drug Des Devel Ther. 2017;11:2325\u201331.","journal-title":"Drug Des Devel Ther"},{"key":"5080_CR49","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/01.mco.0000165004.93707.88","volume":"8","author":"C Deans","year":"2005","unstructured":"Deans C, Wigmore SJ. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care. 2005;8:265\u20139.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"5080_CR50","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1200\/JCO.2012.44.2020","volume":"31","author":"K Ando","year":"2012","unstructured":"Ando K, Takahashi F, Motojima S, et al. Possible role for tocilizumab, an anti\u2013interleukin-6 receptor antibody, in treating cancer cachexia. J Clin Oncol. 2012;31:e69\u201372.","journal-title":"J Clin Oncol"},{"key":"5080_CR51","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/ncpendmet0120","volume":"2","author":"S Bhasin","year":"2006","unstructured":"Bhasin S, Calof OM, Storer TW, et al. Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Rev Endocrinol. 2006;2:146.","journal-title":"Nat Rev Endocrinol"},{"key":"5080_CR52","first-page":"S30","volume":"22","author":"J Crawford","year":"2014","unstructured":"Crawford J, Johnston M, Hancock M, et al. Enobosarm, a selective androgen receptor modulator (SARM) increases lean body mass (LBM) in advanced NSCLC patients: updated results of two pivotal, international phase 3 trials. Support Care Cancer. 2014;22:S30.","journal-title":"Support Care Cancer"},{"issue":"3","key":"5080_CR53","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1136\/bmjspcare-2017-001440","volume":"8","author":"Tora S Solheim","year":"2018","unstructured":"Solheim TS, Laird BJ, Balstad TR, et al. Cancer cachexia: rationale for the MENAC (Multimodal\u2014Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial. BMJ Support Palliat Care. 2018. \n                    https:\/\/doi.org\/10.1136\/bmjspcare-2017-001440\n                    \n                  .","journal-title":"BMJ Supportive & Palliative Care"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5080-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-5080-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5080-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T19:09:04Z","timestamp":1574795344000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-5080-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,27]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["5080"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-5080-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,27]]},"assertion":[{"value":"27 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No approval was required now as the study was focused on conducting a systematic review of previously published literature.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"1174"}}